跳至主要内容
临床试验/NCT02576340
NCT02576340已完成4 期

Spasmolytic (Otilonium Bromide) Use in Upper Gastrointestinal Endoscopy: Randomized Prospective Trial

Konya Meram State Hospital0 个研究点目标入组 400 人开始时间: 2013年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
400
主要终点
motility

研究概览

简要总结

Upper gastrointestinal system endoscopy is widely used for diagnostic approach. To increase the tolerability and compliance of the patient, sedation is applied. There are many studies showing that sedation increases the patient compliance and the tolerability. However, spasmolytic use in GE has not been evaluated yet.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • no hypersensitivity to the agent.

排除标准

  • Emergent cases,the cases with low mental compatibility and pregnant women were excluded from the study. Moreover, the procedures under sedation, cases with disorders decreasing the intestinal motility like hypothyroidism and diabetes were excluded.

研究组 & 干预措施

study

Active Comparator

drug was administered

干预措施: otilonium bromide (Drug)

结局指标

主要结局

motility

时间窗: 3 months

decrease in motility during the procedure (number of peristaltic moves in a minute)

次要结局

  • patient tolerance(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

barış sevinç

M. D.

Konya Meram State Hospital

相似试验